

Supporting information

Important Safety Note:

Safety hazards of all diazoalkanes, described within this manuscript, have not been investigated. However, it should be noted that handling of diazomethane and its derivatives should only be done in a well-ventilated fume cupboard using an additional blast shield. No incidents occurred handling all diazoalkanes during the preparation of this manuscript, yet the reader should be aware of carcinogenicity and potential explosiveness of the herein described diazoalkane derivatives. General safety precautions when working with diazomethane and its derivatives should be followed. Any reactions described in this manuscript should not be performed without strict risk assessment and proper safety precautions.

General: Unless otherwise noted, all commercially available compounds were used as provided without further purification. Chemicals used in this manuscript were purchased from Sigma Aldrich, Fluorochem, Alfa Aesar.

Solvents used in reactions were p.A. grade. Solvents for chromatography were technical grade and distilled prior to use. Analytical thin-layer chromatography (TLC) was performed on Macherey-Nagel silica gel aluminium plates with F-254 indicator, visualised by irradiation with UV light. Column chromatography was performed using silica gel Merck 60 (particle size 0.063 – 0.2 mm). Solvent mixtures are understood as volume/volume.

¹H-NMR, ¹⁹F-NMR and ¹³C-NMR were recorded on a Varian AV400 or AV600 spectrometer in CDCl₃, CD₃OD or DMSO-d₆. Data are reported in the following order: chemical shift (δ) in ppm; multiplicities are indicated br (broadened singlet), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet); coupling constants (J) are in Hertz (Hz).

EI MS data were recorded on a Finnigan SSQ 7000 or Finnigan MAT 95 using EI ionization at 70 eV or on a Shimadzu GCMS sytem (QP 2010 SE and GC2010plus, CP-Sil-8-MS column, 30m, 0.25µm ID, method: 60°C 5min, 20K/min to 300°C and keep for 20min).

HRMS data were recorded on a ThermoFisher Scientific LTQ Orbitrap XL using ESI ionization.

IR spectra were recorded on a Perkin Elmer-100 spectrometer and are reported in terms of frequency of absorption (cm⁻¹).


The following equipment was utilized for the continuous-flow generation of substituted diazomethanes:

Syringe pump: Harvard Apparatus 22 syringe pump, Chemyx Inc. Model Fusion 710.

Micromixer: Little Things Factory, MR Lab, Type: MST

PTFE tubing: CS chromatographie PTFE tubing, Art Nr. 590515, 1/16" AD, 0.8mm ID, max pressure 37 bar. Reactor volume: 0.8 mL / length 1.6 m

General procedure for the preparation of vinyl sulfones



Thiophenol (1 eq, 30 mmol) in ethanol was added to a NaOEt solution (1 eq, 20% w/w), stirred for 30 min at room temperature and cooled down to 0 °C. The solution was added dropwise to 1,2-dibromoethane in ethanol at 0 °C and stirred for 1h at room temperature. NaOEt solution (2.5 eq) was added and the mixture was stirred at 70 °C for 16 h followed by an aqueous workup.

OXONE (3.3 eq) was added to a solution of the crude product in water / methanol and was stirred for 16 h at room temperature. An aqueous workup followed and the product was purified by column chromatography (hexane / ethyl acetate).

General procedure for biphasic batch reactions

A suspension of dipolarophile (0.5 mmol, 1 eq), amine hydrochloride (2 eq) and NaNO₂ (3 eq) in DCM (8 mL) / water (2 mL) was vigorously stirred for 14 h at room temperature. Water (10 mL) and DCM (10 mL) were added. The organic layer was separated and the aqueous layer was extracted two times with DCM. The combined organic layers were dried over Na₂SO₄, evaporated under vacuum and purified by column chromatography (toluene / ethyl acetate).

Procedure for biphasic batch reaction in gram-scale

A suspension of dipolarophile (5.9 mmol, 1 eq), amine hydrochloride (2 eq) and NaNO₂ (3 eq) in DCM (100 mL) / water (20 mL) was vigorously stirred at 0°C and was allowed to warm up to room temperature over night. Water (50 mL) was added. The organic layer was separated and the aqueous layer was extracted two times with DCM. The combined organic layers were washed with brine and dried over Na₂SO₄, evaporated under reduced pressure and purified by column chromatography (hexanes / ethyl acetate).

General procedure for the water-free batch reaction

A solution of amine (4 eq), tBuONO (4.8 eq) and acetic acid (1.6 eq) in chloroform (7 mL) was stirred at time and temperature indicated to form the corresponding diazo compound. The dipolarophile (0.5 mmol, 1 eq) dissolved in chloroform (3 mL) was added to the mixture and stirred for either directly at the beginning or after the time indicated at room temperature. The solvent was evaporated under reduced pressure and purified by column chromatography (toluene / ethyl acetate).

General procedure for the continuous-flow reactions

Two stock solutions are prepared:

- 2,2-Difluoroethylamine (c = 0.2 M, 4 eq) is dissolved in CHCl₃
- tBuONO (c = 0.24 M, 4.8 eq) and AcOH (c = 0.08 M, 0.2 eq) are dissolved in CHCl₃

The stock solutions are transferred into two syringes and placed in a syringe pump and the syringes are connected via PTFE tubing to a micromixer with an internal volume of 0.2 mL that is connected to a self-built microreactor made of PTFE tubing with an internal volume of 0.8 mL. The microreactor is heated up to 55 °C. At a constant flow rate of 50 $\mu\text{L}/\text{min}$ per syringe the reactants are transferred into the microreactor. The outlet is added to a solution of dipolarophile (0.5 mmol) dissolved in 5 mL CHCl_3 .

After complete addition the resulting yellow solution is stirred for 24 h at room temperature. The crude reaction mixture was directly purified by column chromatography (hexanes / ethyl acetate) to yield the desired pyrazolines.




Figure 1: setup of the continuous-flow system (on the left: syringe pump with 2x 10 mL syringes; in the middle: micromixer (Little things factory, MR-Lab type MST) connected to microreactor and back pressure vent (in black); on the right: reaction flask for the cycloaddition reaction

Procedure for the continuous-flow reaction in gram-scale


Two stock solutions are prepared:

- 2,2-Difluoroethylamine ($c = 0.2 \text{ M}$, 4 eq) is dissolved in CHCl_3
- $t\text{BuONO}$ ($c = 0.24 \text{ M}$, 4.8 eq) and AcOH ($c = 0.08 \text{ M}$, 0.2 eq) are dissolved in CHCl_3

Because of the high volume the stock solutions are split up and transferred into four syringes and placed in two syringe pumps. The syringes are connected via PTFE tubing to the micromixer with an internal volume of 0.2 mL and a self-built microreactor made of PTFE tubing with an internal volume of 0.8 mL. With an water bath the microreactor is heated up to 55 °C. At a constant flow rate of 50 $\mu\text{L}/\text{min}$ per syringe the reactants are transferred into the microreactor. The outlet is added to a solution of dipolarophile (5 mmol) dissolved in 30 mL CHCl_3 .

After complete addition the resulting yellow solution is stirred for 24 h at room temperature. The solvent was evaporated under reduced pressure and the crude reaction mixture was directly purified by column chromatography (hexanes / ethyl acetate) to yield the desired pyrazolines.


Table 1: Optimization of reaction conditions in Batch



Entry	X	R	solvent	Eq. amine /NaNO ₂	% yield
1	F	Me	DCM	2/2	>99%
2	F	Me	CHCl ₃	2/2	87%
3	F	Me	1,2-DCE	2/2	70%
4	F	Me	THF	2/2	79%
5	F	Me	Toluene	2/2	83%
6	F	Me	DMF	2/2	89%
7	F	Ph	DCM	2/2	84%
8	F	Ph	DCM	2/3	87%
9	F	Ph	DCM	3/3	67%
10	H	Me	CHCl ₃	2/2	no reaction

reaction conditions: vinyl sulfone (0.5 mmol, 1 eq), fluorinated amine hydrochloride (eq. as indicated) and NaNO₂ (eq. as indicated) in DCM (8 mL) / water (2 mL) was vigorously stirred for 14 h at room temperature; isolated yields after column chromatography.

Table 2. Optimization of the continuous-flow protocol




entry ^[a]	R / X	Solvent	Eq. amine	Yield ^[b]
1	Me / H	DCM	2	22%
2	Me / H	CHCl ₃	2	34%
3	Me / H	CHCl ₃	4	92%
4	Me / F	CHCl ₃	4	61%
5	Ph / H	CHCl ₃	4	93%

[a] reaction conditions: a solution of amine (0.2 M in CHCl₃, eq. as indicated) and a solution of tBuONO and AcOH (2.4 M / 0.08 M in CHCl₃) were placed in two separate syringes and added by syringe pump at a flow rate of 50 µL/min for each syringe into a microreactor (residence time 10 min, temperature 55 °C). The outlet was connected via a back pressure regulator (20 psi) to a reaction flask containing the vinyl sulfone (0.5 mmol) in CHCl₃ and stirred for 14 h at room temperature. [b] isolated yields after column chromatography


Optimization reactions for Donor-Acceptor fluorinated diazo compounds

phase transfer protocol




water-free protocols

domino reaction




one-pot reaction



Physical data


Starting Material

((vinylsulfonyl)methyl)benzene




^1H -NMR (600 MHz, CDCl_3): δ = 7.42 – 7.31 (m, 5H), 6.50 (dd, J = 16.8, 9.8 Hz, 1H), 6.30 (d, J = 16.6 Hz, 1H), 6.09 (d, J = 9.9 Hz, 1H), 4.24 (s, 2H) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 135.1, 131.2, 131.1, 130.8, 129.0, 128.9, 128.8, 127.6, 61.0 ppm; IR (KBr): ν = 3055, 1492, 1455, 1384, 1305, 1260, 1202, 1156, 1114, 1018, 971, 925, 883, 789, 734, 696 cm^{-1} ; MS-EI: m/z = 181.9.

1-(vinylsulfonyl)-4-methyl-benzene




^1H -NMR (600 MHz, CDCl_3): δ = 7.80 – 7.74 (m, 2H), 7.37 – 7.32 (m, 2H), 6.63 (dd, J = 16.5, 9.9 Hz, 1H), 6.40 (d, J = 16.5 Hz, 1H), 5.99 (d, J = 9.9 Hz, 1H), 2.42 (d, J = 0.9 Hz, 3H) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 144.7, 138.7, 130.0, 127.9, 127.2, 125.2, 21.6 ppm; IR (KBr): ν = 3345, 3015, 2934, 2296, 2085, 1741, 1560, 1428, 1370, 1284, 1107, 956, 865, 758 cm^{-1} ; MS-EI: m/z = 182.0.

1-(vinylsulfonyl)-4-fluoro-benzene




^1H -NMR (600 MHz, CDCl_3): δ = 7.96 – 7.81 (m, 2H), 7.30 – 7.10 (m, 2H), 6.62 (dd, J = 16.5, 9.8 Hz, 1H), 6.43 (d, J = 16.6 Hz, 1H), 6.03 (d, J = 9.7 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = -103.46 (m) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 165.8 (d, J = 256.6 Hz), 138.3, 130.8, 130.8, 128.0, 117.8, 116.6 ppm; IR (KBr): ν = 3105, 3063, 2106, 1589, 1492, 1383, 1318, 1291, 1234, 1145, 1087, 975, 837, 744, 705, 671 cm^{-1} ; MS-EI: m/z = 185.8.

1-(vinylsulfonyl)-4-chloro-benzene



^1H -NMR (600 MHz, CDCl_3): δ = 7.88 – 7.78 (m, 2H), 7.57 – 7.47 (m, 2H), 6.64 (dd, J = 16.5, 9.8 Hz, 1H), 6.47 (d, J = 16.6, 1H), 6.07 (d, J = 9.8, 1H) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 140.4, 138.1, 138.0, 129.7, 129.4, 128.4 ppm; IR (KBr): ν = 3073, 2326, 2095, 1743, 1578, 1474, 1382, 1309, 1141, 977, 830, 760, 659 cm^{-1} ; MS-EI: m/z = 201.8.


1-(vinylsulfonyl)-4-methoxy-benzene



^1H -NMR (400 MHz, CDCl_3): δ = 7.87 – 7.73 (m, 2H), 7.04 – 6.94 (m, 2H), 6.62 (dd, J = 16.5, 9.8 Hz, 1H), 6.37 (d, J = 16.5 Hz, 1H), 5.95 (d, J = 9.8 Hz, 1H), 3.86 (s, 3H) ppm; ^{13}C -NMR (100 MHz, CDCl_3): δ = 163.7, 138.9, 130.9, 130.1, 126.6, 114.5, 55.7 ppm; IR (KBr): ν = 3060,


2958, 2851, 1581, 1493, 1466, 1415, 1380, 1292, 1254, 1137 1087, 1015, 966, 832, 803, 740, 672 cm^{-1} ; MS-EI: $m/z = 198.0$.

1-(vinylsulfonyl)-3-methyl-benzene



^1H -NMR (600 MHz, CDCl_3): $\delta = 8.05$ (dd, $J = 8.0, 1.6$ Hz, 1H), 7.57 – 7.27 (m, 3H), 6.65 (dd, $J = 16.5, 9.9$ Hz, 1H), 6.45 (dd, $J = 16.5, 1.6$ Hz, 1H), 6.10 (d, $J = 9.8$ Hz, 1H), 2.59 (s, 3H) ppm; ^{13}C -NMR (151 MHz, CDCl_3): $\delta = 138.3, 137.9, 137.1, 133.9, 132.6, 129.7, 128.0, 126.7, 20.2$ ppm; IR (KBr): $\nu = 3053, 2334, 2097, 1740, 1603, 1456, 1386, 1302, 1130, 972, 865, 732$ cm^{-1} ; MS-EI: $m/z = 181.9$.


1-(vinylsulfonyl)-2-methyl-benzene



^1H -NMR (600 MHz, CDCl_3): $\delta = 7.74 - 7.64$ (m, 2H), 7.48 – 7.38 (m, 2H), 6.65 (dd, $J = 16.5, 9.8$ Hz, 1H), 6.45 (d, $J = 16.6$ Hz, 1H), 6.03 (d, $J = 9.9$ Hz, 1H), 2.43 (s, 3H) ppm; ^{13}C -NMR (151 MHz, CDCl_3): $\delta = 139.6, 139.3, 138.5, 134.4, 129.2, 128.2, 127.6, 125.0, 21.3$ ppm; IR (KBr): $\nu = 3057, 2335, 2097, 1740, 1595, 1457, 1383, 1298, 1134, 1055, 972, 737$ cm^{-1} ; MS-EI: $m/z = 181.9$.

Trifluoromethyl-substituted pyrazolines


3-(methylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



^1H -NMR (600 MHz, CDCl_3): $\delta = 4.57 - 4.44$ (m, 1H), 3.40 (dd, $J = 17.8, 12.3$ Hz, 1H), 3.28 (dd, $J = 17.8, 8.1$ Hz, 1H), 3.18 (s, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): $\delta = -77.16$ (d, $J = 6.8$ Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): $\delta = 151.1, 124.1$ (q, $J = 279.5$ Hz), 61.8 (q, $J = 31.8$ Hz), 41.0,


31.0 ppm; IR (KBr): ν = 3345, 3015, 2943, 2296, 2085, 1741, 1560, 1428, 1370, 1284, 1107, 956, 865, 758 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_5\text{H}_7\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 239.00708, found 239.00725.

3-(ethylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 4.62 – 4.44 (m, 1H), 3.41 (dd, J = 17.8, 12.3 Hz, 1H), 3.34 – 3.23 (m, 3H), 1.41 (t, J = 7.5 Hz, 3 H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –77.35 (d, J = 6.8 Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 124.0 (q, J = 2.79.5), 61.6 (q, J = 31.7 Hz), 48.1, 31.6, 29.7, 6.8 ppm; IR (KBr): ν = 3600, 3335, 2937, 2324, 2111, 1924, 1738, 1631, 1569, 1415, 1379, 1280, 1121, 951, 871, 775, 719 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_6\text{H}_9\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 258.0235, found 258.0229.

3-(benzylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 7.42 – 7.35 (m, 5H), 6.52 (b, 1H), 4.50 (d, J = 4.5 Hz, 2H), 4.39 – 4.33 (m, 1H), 3.01 (dd, J = 17.9, 12.5 Hz, 1H), 2.72 (dd, J = 17.9, 8.6 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –6.82 (d, J = 6.5 Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 131.1, 129.3, 129.0, 126.5, 123.9 (q, J = 279.4 Hz), 61.8 (q, J = 32.0 Hz) 60.9, 33.0 ppm; IR (KBr): ν = 3328, 3079, 2978, 2927, 2853, 2300, 2108, 1988, 1902, 1826, 1738, 1569, 1497, 1425, 1385, 1319, 1286, 1192, 1156, 1128, 1102, 981, 953, 925, 889, 867, 829, 784, 723, 689, 680 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{11}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 315.0389, found 315.0386.

3-(phenylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 8.00 – 7.92 (m, 2H), 7.74 – 7.54 (m, 3H), 6.57 (b, 1H), 4.54 – 4.40 (m, 1H), 3.32 (dd, J = 17.6, 12.4 Hz, 1H), 3.14 (dd, J = 17.7, 8.1, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –77.25 (d, J = 6.7 Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 150.7, 137.9, 134.4, 129.5, 128.4, 123.9 (q, J = 279.8 Hz), 62.3, 31.8 ppm; IR (KBr): ν = 3322, 3068, 2865, 2322, 2078, 1916, 1702, 1623, 1573, 1443, 1397, 1288, 1127, 1072, 997, 946, 866, 754, 719, 686 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{10}\text{H}_9\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 301.02191, found 301.02290.

3-tosyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 7.87 – 7.77 (m, 2H), 7.36 (d, J = 8 Hz, 2H), 4.51 – 4.37 (m, 1H), 3.30 (dd, J = 17.6, 12.2 Hz, 1H), 3.12 (dd, J = 17.6, 8.2 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –77.21 (d, J = 6.7 Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 134.8, 130.1, 128.5, 124.0 (d, J = 289.4 Hz), 62.1 (q, J = 31.8 Hz), 31.8, 21.7 ppm; IR (KBr): ν = 3333, 2961, 2306, 2083, 1926, 1737, 1580, 1400, 1286, 1131, 800, 685 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{11}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 315.03857, found 315.03855.

3-((4-fluorophenyl)sulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 8.03 – 7.95 (m, 2H), 7.32 – 7.25 (m, 2H), 4.47 (m, 1H), 3.35 (dd, J = 17.6, 12.3, 1H), 3.17 (dd, J = 17.6, 7.9 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –77.34 (d, J = 6.7 Hz, 3F), –101.9 (s, 1F) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 167.1, 165.4, 150.8, 133.9, 131.4, 123.9 (q, J = 279.8 Hz), 116.9, 62.2 (q, J = 31.9 Hz), 31.7 ppm; IR (KBr): ν = 3349, 2981, 2307, 2092, 1738, 1569, 1383, 1286, 1139, 964, 843, 688 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{10}\text{H}_8\text{O}_2\text{N}_2\text{F}_4\text{NaS}$: 319.01456, found 319.01348.

3-((4-chlorophenyl)sulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 7.96 – 7.86 (m, 2H), 7.58 – 7.52 (m, 2H), 4.47 (m, 1H), 3.34 (dd, J = 17.6, 12.3 Hz, 1H), 3.18 (dd, J = 17.6, 8.0 Hz, 1H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = -77.32 (d, J = 6.8 Hz) ppm; $^{13}\text{C-NMR}$ (151MHz, CDCl_3): δ = 150.6, 141.4, 136.3, 129.9, 129.8, 124.4 (q, J = 279.8), 62.2 (q, J = 32.1 Hz), 31.7 ppm; IR (KBr): ν = 3321, 3096, 3011, 2868, 2295, 2111, 1914, 1739, 1646, 1574, 1436, 1396, 1284, 1200, 1130, 1079, 1010, 943, 868, 825, 753, 695 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{11}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 315.03857, found 315.03855.

3-((4-methoxyphenyl)sulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 7.94 – 7.85 (m, 2H), 7.06 – 6.99 (m, 2H), 4.44 (m, 1H), 3.89 (s, 3H), 3.32 (dd, J = 17.6, 12.2 Hz, 1H), 3.16 (dd, J = 17.6, 8.1 Hz, 1H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = -77.18 (d, J = 6.8 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 164.4, 151.71, 130.8, 129.0, 127.5 (q, J = 279.9 Hz), 114.7, 62.1 (q, J = 31.8 Hz), 55.8, 31.8 ppm; IR (KBr): ν = 3313, 2969, 2586, 2294, 2070, 1914, 1738, 1588, 1496, 1446, 1264, 1125, 1024, 940, 831, 676 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{11}\text{O}_3\text{N}_2\text{F}_3\text{NaS}$: 331.03360, found 331.03347.


3-((*m*-tolylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 8.06 (dd, J = 7.9, 1.4 Hz, 1H), 7.56 (td, J = 7.5, 1.4 Hz, 1H), 7.45 – 7.33 (m, 2H), 4.52 – 4.33 (m, 1H), 3.32 (dd, J = 17.7, 12.3 Hz, 1H), 3.13 (dd, J = 17.7, 7.7 Hz, 1H), 2.61 (s, 3H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = -77.44 (d, J = 6.9 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 150.6, 139.5, 135.7, 134.5, 132.8, 130.2, 126.6, 124.0 (q, J = 279.9

Hz), 61.9 (q, $J = 31.9$ Hz), 31.7, 20.3 ppm; IR (KBr): $\nu = 3309, 2929, 2087, 1697, 1431, 1286, 1133, 855, 781, 686$ cm⁻¹; HRMS (ESI): m/z calcd for C₁₁H₁₁O₂N₂F₃NaS: 315.03812, found 315.03855.


3-(*o*-tolylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1*H*-pyrazole



¹H-NMR (600 MHz, CDCl₃): $\delta = 7.77 - 7.73$ (m, 2H), 7.51 – 7.46 (m, 2H), 4.46 (ddq, $J = 12.2, 8.0, 6.8$ Hz, 1H), 3.32 (dd, $J = 17.6, 12.3$ Hz, 1H), 3.15 (dd, $J = 17.7, 8.1$ Hz, 1H), 2.45 (s, 3H) ppm; ¹⁹F-NMR (564 MHz, CDCl₃): $\delta = -77.21$ (d, $J = 6.6$ Hz) ppm; ¹³C-NMR (151 MHz, CDCl₃): $\delta = 150.9, 139.9, 137.7, 135.3, 129.3, 128.7, 125.5, 124.0$ (q, $J = 279.6$ Hz), 62.2 (q, $J = 32.0$ Hz), 31.9, 31.3 ppm; IR (KBr): $\nu = 3350, 2969, 2302, 2089, 1739, 1555, 1282, 1141, 869, 693$ cm⁻¹; HRMS (ESI): m/z calcd for C₁₁H₁₁O₂N₂F₃NaS: 315.03851, found 315.03855.


Difluoromethyl-substituted pyrazolines

5-(difluoromethyl)-3-(methylsulfonyl)-4,5-dihydro-1*H*-pyrazole




¹H-NMR (600 MHz, CD₃OD): $\delta = 6.00 - 5.75$ (td, $J = 55.7, 4.4$ Hz, 1H), 4.40 – 4.23 (m, 1H), 3.25 (dd, $J = 17.3, 12.4$ Hz, 1H), 3.13 (s, 3H) ppm; ¹⁹F-NMR (564 MHz, CD₃OD) $\delta -127.30$ (ddd, $J = 289.4, 55.8, 12.1$ Hz), -128.59 (ddd, $J = 289.5, 55.8, 10.5$ Hz). ¹³C-NMR (151 MHz, CD₃OD): $\delta = 148.8, 115.1$, (t, $J = 242.0$ Hz), 62.7 (t, $J = 24.1$ Hz), 40.0, 30.5 – 28.5 (m) ppm; IR (KBr): $\nu = 3323, 3022, 2936, 2281, 2085, 1564, 1393, 1298, 1161, 1099, 1059, 1026, 941, 659$ cm⁻¹; HRMS (ESI): m/z calcd for C₅H₈F₂N₂NaO₂S: 221.01668, found 221.10910.

5-(difluoromethyl)-3-(ethylsulfonyl)-4,5-dihydro-1*H*-pyrazole




$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 6.68 – 6.32 (b, 1H), 5.74 (td, J = 55.5, 4.6 Hz, 1H), 4.29 (m, 1H), 3.31 – 3.20 (m, 3H), 3.08 (dd, J = 17.5, 8.4 Hz, 1H), 1.38 (t, J = 7.5 Hz, 3 H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = -125.34 (ddd, J = 290.8, 55.6, 12.1 Hz), -126.34 (ddd, J = 290.9, 55.4, 9.5 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 149.5, 114.4 (t, J = 243.9 Hz), 62.6 (t, J = 24.3 Hz), 48.0, 31.3, 6.7 ppm; IR (KBr): ν = 3600, 3337, 2982, 2323, 2106, 1923, 1739, 1627, 1565, 1412, 1305, 1224, 1055, 871, 775, 719 cm^{-1} ; MS (EI): m/z (%): 212.0 ([M], 81%), 161.1 ([M-CF₂H], 100%).

3-(benzylsulfonyl)-5-(difluoromethyl)-4,5-dihydro-1H-pyrazole




$^1\text{H-NMR}$ (600 MHz, DMSO-d_6): δ = 8.82 (br, 1H), 7.35 (dtt, J = 10.0, 6.6, 3.6 Hz, 5H), 5.98 (dt, J = 55.5, 4.0 Hz, 1H), 4.61 (s, 2H), 4.37 – 4.25 (m, 1H), 3.03 (dd, J = 17.2, 12.9 Hz, 1H), 2.79 (dd, J = 17.2, 9.3 Hz, 1H) ppm; $^{19}\text{F-NMR}$ (564 MHz, DMSO-d_6): δ = -125.89 (ddd, J = 284.5, 55.6, 11.7 Hz), -126.17 (ddd, J = 284.6, 55.4, 12.5 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, DMSO-d_6): δ = 146.4, 131.7, 128.9, 128.4, 115.5 (t, J = 241.5 Hz), 78.5, 62.5 (t, J = 23.3 Hz), 59.6, 31.8 ppm; IR (KBr): ν = 3336, 2978, 2932, 2658, 2311, 2104, 1904, 1738, 1567, 1496, 1452, 1401, 1307, 1251, 1206, 1157, 1057, 877, 783, 701 cm^{-1} ; MS (EI): m/z (%): 273.9 ([M], 5%), 91.0 ([M-C₄H₅F₂N₂O₂S], 100%); HRMS (ESI): m/z calcd for C₁₁H₁₂O₂N₂F₂NaS: 297.04834, found 297.04798.

5-(difluoromethyl)-3-(phenylsulfonyl)-4,5-dihydro-1H-pyrazole




$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 8.09 – 7.82 (m, 2H), 7.74 – 7.62 (m, 1H), 7.61 – 7.51 (m, 2H), 5.64 (td, J = 55.6, 5.3 Hz, 1H), 4.30 – 4.15 (m, 1H), 3.21 (dd, J = 17.3, 11.8, 1H), 3.00 (dd, J = 17.4, 8.6 Hz, 1H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = –124.42 (ddd, J = 292.6, 55.8, 11.7 Hz), –125.55 (ddd, J = 292.6, 55.3, 8.1 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 151.1, 137.9, 134.4, 129.5, 128.4, 114.2 (t, J = 244.1 Hz), 64.3 – 61.0 (m), 331. – 28.2 (m) ppm; IR (KBr): ν = 3925, 3321, 2857, 1561, 1442, 1319, 1290, 1171, 1134, 1075, 1045, 1006, 945, 861, 791, 718, 691 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{10}\text{H}_{10}\text{F}_2\text{N}_2\text{NaO}_2\text{S}$: 283.03233, found 283.03171.

5-(difluoromethyl)-3-tosyl-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CD_3OD): δ = 7.91 – 7.72 (m, 2H), 7.44 (d, J = 8.1 Hz, 2H), 5.78 (td, J = 55.6, 4.1 Hz, 1H), 4.27 (tddd, J = 12.6, 10.7, 4.1 Hz, 1H), 3.12 (ddd, J = 17.2, 12.5 Hz, 1H), 2.93 (dd, J = 17.3 Hz, 9.0 Hz, 1H), 2.44 (s, 3H) ppm; $^{19}\text{F-NMR}$ (376 MHz, CD_3OD): δ = –127.76 (ddd, J = 289.0, 55.7, 12.1 Hz), –128.74 (m) ppm; $^{13}\text{C-NMR}$ (151 MHz, CD_3OD): δ = 148.5, 145.4, 125.8, 129.8, 127.8, 117.7 – 112.6 (m), 62.8 (t, J = 23.9 Hz), 30.3, 20.1 ppm; IR (KBr): ν = 3341, 2974, 2325, 2103, 1920, 1741, 1594, 1381, 1314, 1141, 1064, 957, 868, 810, 666 cm^{-1} ; MS (EI): m/z (%): 274.0 ([M], 4%), 223.0 ([M- CF_2H], 7%), 155.0 ([M- $\text{C}_4\text{H}_5\text{F}_2\text{N}_2$], 11%), 91.0 ([M- $\text{C}_4\text{H}_5\text{F}_2\text{N}_2\text{O}_2\text{S}$], 100%); HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{12}\text{O}_2\text{N}_2\text{F}_2\text{NaS}$: 297.04868, found 297.04798.


5-(difluoromethyl)-3-((4-fluorophenyl)sulfonyl)-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 8.01 – 7.92 (m, 2H), 7.30 – 7.21 (m, 2H), 5.68 (td, J = 55.5, 5.0 Hz, 1H), 4.27 (ttd, J = 11.9, 8.6, 5.0 Hz, 1H), 3.21 (dd, J = 17.4, 12.1 Hz, 1H), 3.01 (dd, J = 17.4, 8.7 Hz, 1H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = –102.11 (td, J = 8.2, 4.1 Hz), –124.81 (ddd, J = 291.8, 55.6, 11.8 Hz), –126.00 (ddd, J = 292.0, 55.3, 8.6 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 167.1, 165.3, 150.8, 134.1, 131.3, 116.9, 116.2, 114.3 (t, J = 244.1 Hz), 63.4 – 62.9 (m),


31.3 ppm; IR (KBr): ν = 3346, 3106, 2983, 2327, 2078, 1914, 1743, 1587, 1492, 1406, 1324, 1234, 1146, 1064, 955, 833, 670 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{10}\text{H}_9\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 301.02229, found 301.02290.

3-((4-chlorophenyl)sulfonyl)-5-(difluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CD_3OD): δ = 7.91 – 7.84 (m, 2H), 7.68 – 7.60 (m, 2H), 5.78 (td, J = 55.6, 4.1 Hz, 1H), 4.29 (td, J = 12.7, 11.0, 8.9, 4.1 Hz, 1H), 3.14 (dd, J = 17.3, 12.6 Hz, 1H), 2.95 (dd, J = 17.3, 9.0 Hz, 1H) ppm; ^{19}F -NMR (376 MHz, CD_3OD): δ = -128.00 (ddd, J = 289.2, 55.5, 12.0 Hz), -129.13 (ddd, J = 289.2, 55.7, 10.9 Hz) ppm; ^{13}C -NMR (151 MHz, CD_3OD): δ = 147.6, 140.3, 137.7, 129.4, 114.9 (t, J = 242.2 Hz), 63.0 (q, J = 24.1 Hz), 30.2 ppm; IR (KBr): ν = 3333, 2993, 2640, 2323, 2105, 1740, 1566, 1397, 1311, 1057, 826, 753 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{10}\text{H}_9\text{O}_2\text{N}_2\text{ClF}_2\text{NaS}$: 316.99344, found 316.99335.

5-(difluoromethyl)-3-((4-methoxyphenyl)sulfonyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ 7.93 – 7.86 (m, 2H), 7.06 – 7.03 (m, 2H), 5.65 (td, J = 55.6, 5.3 Hz, 1H), 4.32 – 4.19 (m, 1H), 3.89 (s, 3H), 3.22 (dd, J = 17.4, 11.8 Hz, 1H), 3.01 (dd, J = 17.4, 8.7 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = -124.15 (ddd, J = 292.3, 55.9, 12.0 Hz), -125.31 (ddd, J = 292.4, 55.3, 7.7 Hz) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 164.3, 152.1, 130.8, 129.2, 114.7, 114.4 (t, J = 244.0 Hz), 63.4 – 62.9 (m), 55.8, 31.5 ppm; IR (KBr): ν = 3612, 3339, 2949, 2847, 2578, 2324, 2109, 1999, 1919, 1742, 1587, 1495, 1456, 1309, 1262, 1129, 1066, 956, 833, 729, 670 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{12}\text{O}_3\text{N}_2\text{F}_2\text{NaS}$: 313.04294, found 313.04289.

5-(difluoromethyl)-3-(*m*-tolylsulfonyl)-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 7.79 – 7.72 (m, 2H), 7.51 – 7.43 (m, 2H), 5.67 (td, J = 55.6, 5.1 Hz, 1H), 4.25 (ttd, J = 11.9, 8.5, 5.1 Hz, 1H), 3.20 (dd, J = 17.4, 12.0 Hz, 1H), 3.00 (ddd, J = 17.3, 8.7, 0.7 Hz, 1H), 2.44 (s, 3H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = –124.39 (ddd, J = 291.9, 55.7, 11.8 Hz), –125.76 (ddd, J = 292.0, 55.4, 8.3 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 151.1, 139.8, 137.9, 135.2, 129.3, 128.6, 125.5, 114.3 (t, J = 243.9 Hz), 63.9 – 62.1 (m), 31.5, 21.3 ppm; IR (KBr): ν = 3343, 2975, 2333, 2096, 2000, 1915, 1819, 1565, 1416, 1307, 1218, 1125, 1064, 956, 865, 787, 691 cm^{-1} ; HRMS (ESI): m/z calcd for: $\text{C}_{11}\text{H}_{12}\text{O}_2\text{N}_2\text{F}_2\text{NaS}$: 297.04810, found 297.04798.


5-(difluoromethyl)-3-(*o*-tolylsulfonyl)-4,5-dihydro-1H-pyrazole



$^1\text{H-NMR}$ (600 MHz, CDCl_3): δ = 8.04 (dd, J = 7.9, 1.4 Hz, 1H), 7.55 (td, J = 7.5, 1.5 Hz, 1H), 7.43 – 7.31 (m, 2H), 5.68 (td, J = 55.5, 4.8 Hz, 1H), 4.26 (ttd, J = 11.9, 8.7, 4.8 Hz, 1H), 3.17 (dd, J = 17.4, 12.0 Hz, 1H), 2.97 (dd, J = 17.4, 8.4 Hz, 1H), 2.60 (s, 3H) ppm; $^{19}\text{F-NMR}$ (564 MHz, CDCl_3): δ = –125.13 (ddd, J = 291.1, 55.7, 12.0 Hz), –126.13 (ddd, J = 291.1, 55.3, 8.9 Hz) ppm; $^{13}\text{C-NMR}$ (151 MHz, CDCl_3): δ = 150.6, 139.4, 135.8, 134.4, 132.8, 130.1, 126.6, 114.3 (t, J = 244.0 Hz), 64.2 – 61.7 (m), 31.2, 20.3 ppm; IR (KBr): ν = 3343, 3064, 2978, 2331, 2099, 1926, 1739, 1566, 1455, 1308, 1152, 1058, 955, 872, 803, 763, 696 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{12}\text{O}_2\text{N}_2\text{F}_2\text{NaS}$: 297.04813, found 297.04798.


branched pyrazolines

5-methyl-3-(methylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 3.42 (d, J = 17.6 Hz, 1H), 3.17 (s, 3H), 3.04 (dt, J = 17.6, 0.9 Hz, 1H), 1.54 – 1.49 (m, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –80.27 (s) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 150.0, 125.3 (q, J = 281.8 Hz), 80.2, 69.3 (q, J = 29.4 Hz), 40.9, 37.9, 20.4 ppm; IR (KBr): ν = 3254, 2095, 1717, 1149, 778 cm^{-1} ; MS (EI): m/z (%): 229.9 (8%), 161.0 (81%).

3-(methylsulfonyl)-5-phenyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



^1H -NMR (600 MHz, CDCl_3): δ = 7.50 – 7.33 (m, 5 H), 3.88 (d, J = 17.8 Hz, 1H), 3.54 (dq, J = 17.8, 1.0 Hz, 1H), 3.17 (s, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –79.02 (s) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 150.1, 135.5, 129.4, 129.1, 127.9, 125.0 (q, J = 285.0 Hz), 74.2 (q, J = 28.2 Hz), 41.0, 39.4 ppm; IR (KBr): ν = 3569, 3325, 3020, 2323, 2093, 1709, 1585, 1429, 1298, 1151, 977, 867, 725 cm^{-1} ; MS (EI): m/z (%): 291.9 ([M], 10%), 223.0 ([M- CF_3], 100%).


3-(methylsulfonyl)-5-(*p*-tolyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



^1H -NMR (600 MHz, CDCl_3): δ = 7.29 – 7.22 (m, 4H), 3.85 (d, J = 17.7 Hz, 1H), 3.53 (dq, J = 17.8, 1.0 Hz, 1H), 3.17 (s, 3H), 2.37 (s, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = –78.94 (s) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 150.1, 139.5, 132.4, 129.7, 127.9, 125.1 (q, J = 284.7 Hz), 74.5 – 73.8 (m), 41.1, 39.4, 21.1 ppm; IR (KBr): ν = 3331, 3026, 2930, 2287, 2185, 2077, 1757,


1701, 1619, 1575, 1419, 1306, 1160, 1018, 989, 958, 876, 814, 759, 726, 697 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{12}\text{H}_{13}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 329.0548, found 329.0542.

5-(4-fluorophenyl)-3-(methylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole




^1H -NMR (600 MHz, CDCl_3): δ = 7.36 (hept, J = 3.5 Hz, 2H), 7.10 (dt, J = 8.6, 4.3 Hz, 1H), 3.86 (ddd, J = 17.8, 8.0, 2.9 Hz, 1H), 3.47 (dd, J = 18.1, 6.8 Hz, 1H), 3.18 (s, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = -111.62 (s, 3F), -79.39 (s, 1F) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 146.5, 140.4, 128.2, 125.9, 72.1 (d, J = 27.8 Hz), 40.1, 34.6, 28.3 ppm; IR (KBr): ν = 3328, 2934, 2306, 2089, 1903, 1733, 1594, 1514, 1422, 1299, 1152, 981, 831, 759 cm^{-1} ; MS (EI): m/z (%): 310.9 ([M], 6%), 133.0 ([M- $\text{C}_8\text{H}_4\text{F}_4$], 100%); HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{10}\text{O}_2\text{N}_2\text{F}_4\text{NaS}$: 333.0298, found 333.0291.

3-(methylsulfonyl)-5-phenethyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



^1H -NMR (600 MHz, CDCl_3): δ = 7.41 – 7.15 (m, 4H), 3.41 (d, J = 18.0 Hz, 1H), 3.29 – 3.20 (m, 1H), 3.16 (s, 3H) 2.68 (dddd, J = 21.1, 16.7, 13.7, 8.4 Hz, 2H), 2.11 (dd, J = 9.4, 7.6 Hz, 1H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = -79.17 (s) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 149.4, 139.6, 128.8, 127.9 – 122.2 (m), 126.7, 72.1 (q, J = 28.1 Hz), 41.0, 35.5, 34.7, 29.0 ppm; IR (KBr): ν = 3329, 3028, 2932, 2866, 2655, 2327, 2181, 2114, 1994, 1749, 1570, 1497, 1451, 1414, 1305, 1161, 1123, 1049, 989, 957, 866, 817, 758, 700 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{13}\text{H}_{16}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 321.08850, found 321.08791.

5-methyl-3-(phenylsulfonyl)-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazole



^1H -NMR (600 MHz, CDCl_3): δ = 8.03 – 7.88 (m, 2H), 7.77 – 7.67 (m, 1H), 7.62 – 7.53 (m, 2H), 3.27 (d, J = 17.5 Hz, 1H), 2.97 (d, J = 17.5, 1.0 Hz, 1H), 1.45 (d, J = 1.1 Hz, 3H) ppm; ^{19}F -NMR (564 MHz, CDCl_3): δ = -80.33 (s) ppm; ^{13}C -NMR (151 MHz, CDCl_3): δ = 149.6, 138.0, 134.4, 129.4, 128.3, 128.2 – 121.5 (m), 69.7 (q, J = 29.2 Hz), 38.7, 20.2 ppm; IR (KBr): ν = 3887, 3368, 2340, 2093, 1728, 1377, 1143, 731 cm^{-1} ; HRMS (ESI): m/z calcd for $\text{C}_{11}\text{H}_{12}\text{O}_2\text{N}_2\text{F}_3\text{NaS}$: 315.03918, found 315.03855.

